New Therapies Reshape Treatment for Familial Chylomicronemia Syndrome
Table of Contents
A growing number of treatment options are prompting clinicians to reassess established algorithms for managing familial chylomicronemia syndrome (FCS), a rare genetic disorder causing severely elevated triglyceride levels. the field recently welcomed the FDA approval of plozasiran (Redemplo) in November 2025, marking the second approved therapy for this challenging condition.
The integration of these new agents – plozasiran and olezarsen (Tryngolza) – into clinical practice is the focus of a new video series, with experts emphasizing the need for a patient-centered approach. A leading cardiologist explained that while these approvals represent significant scientific advancements, their successful implementation requires careful consideration of individual patient needs and established treatment principles.
The Cornerstone of Care: Diet Remains Essential
Historically, managing FCS relied heavily on strict dietary restrictions, frequently enough demanding patients adhere to extremely low-fat intake. Despite the availability of more potent medications,nutritional management remains a foundational element of care. Experts reiterate that a carefully managed diet not only supports the effectiveness of medication but also helps to minimize the risk of pancreatitis, a serious complication associated with FCS.
Integrating New Therapies into Practice
Practical integration of these therapies requires a collaborative approach. Consistent lipid monitoring is crucial, alongside clear communication between lipid specialists, cardiologists, and nutritionists. Medication selection should be tailored to each patient, taking into account factors such as personal preference, access to care, safety profiles, and previous treatment responses.
Clinicians have a vital role in providing structured education to patients, ensuring they understand the continued importance of dietary management even while receiving advanced therapies. This thorough approach aims to optimize treatment outcomes and improve the quality of life for individuals living with FCS.
Disclosure Details
Relevant disclosures were reported for both experts involved in the discussion. Dr. Christie Ballantyne has affiliations with arrowhead Pharmaceuticals, Inois, merck, Novartis, Novo Nordisk, New Amsterdam, Esperion, AstraZeneca, Eli Lilly, and others. Viet Le, DMSc, PA-C, has disclosed relationships with Amarin, Bayer, Esperion, Idorsia, Janssen, Novo Nordisk, Novartis, Lexicon Pharmaceuticals, and Pfizer.
References:
- Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals Announces FDA approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS). Arrowhead Pharmaceuticals, Inc. Published November 19, 2025. Accessed November 25, 2025.
- Virani SS,Morris PB,agarwala A,et al. 2021 ACC Expert Consensus decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of cardiology Solution Set oversight Committee. J Am Coll Cardiol. 2021;78(9):960-993. doi:10.1016/j.jacc.2021.06.011
- US Food and Drug Administration. FDA approves Tryngolza (olezarsen).U.S. Food and Drug Administration. Published December 19, 2024. Accessed November 25, 2025.
- Latest Advances in Alzheimer’s Disease Treatment and Diagnosis (news-usa.today)
